BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim H, Huh J, Jeon H, Choi D, Han J, Kim Y, Jung Y. N,N'-Bis(5-aminosalicyl)-L-cystine is a potential colon-specific 5-aminosalicylic acid prodrug with dual therapeutic effects in experimental colitis. J Pharm Sci. 2009;98:159-168. [PMID: 18399548 DOI: 10.1002/jps.21404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Chopade SS, Dhaneshwar SS. Determination of the mitigating effect of colon-specific bioreversible codrugs of mycophenolic acid and aminosugars in an experimental colitis model in Wistar rats. World J Gastroenterol 2018; 24(10): 1093-1106 [PMID: 29563754 DOI: 10.3748/wjg.v24.i10.1093] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Mura C, Nácher A, Merino V, Merino-sanjuán M, Manconi M, Loy G, Fadda A, Díez-sales O. Design, characterization and in vitro evaluation of 5-aminosalicylic acid loaded N-succinyl-chitosan microparticles for colon specific delivery. Colloids and Surfaces B: Biointerfaces 2012;94:199-205. [DOI: 10.1016/j.colsurfb.2012.01.030] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
3 Jung Y, Kim YM. What should be considered on design of a colon-specific prodrug? Expert Opinion on Drug Delivery 2010;7:245-58. [DOI: 10.1517/17425240903490401] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
4 McConnell EL, Liu F, Basit AW. Colonic treatments and targets: issues and opportunities. J Drug Target 2009;17:335-63. [PMID: 19555265 DOI: 10.1080/10611860902839502] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
5 Kim W, Nam J, Lee S, Jeong S, Jung Y. 5-Aminosalicylic Acid Azo-Linked to Procainamide Acts as an Anticolitic Mutual Prodrug via Additive Inhibition of Nuclear Factor kappaB. Mol Pharm 2016;13:2126-35. [PMID: 27112518 DOI: 10.1021/acs.molpharmaceut.6b00294] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]